San Francisco, CA (PressExposure) September 17, 2013 -- Tom D. Heightman, Senior Director of Medicinal Chemistry at Astex Pharmaceuticals to Present on "SGI-110, A Novel Second Generation Hypomethylating Agent in Phase 2 Clinical Development for Hematological and Solid Tumor Malignancies" at the 3rd Cancer Epigenetics Conference on November 6-8, 2013 in San Francisco, CA by GTC.
Tom Heightman studied Chemistry at Oxford, and gained his PhD in organic synthesis and enzymology at the ETH in Zurich. In 1998 he joined GlaxoSmithKline in Harlow, UK, where he held positions of increasing responsibility, becoming Head of Lead Discovery for GSK's Neurology CEDD 2006-2008. During this time he made significant scientific and leadership contributions to the discovery of over a dozen pre-clinical candidates across multiple therapeutic areas, four of which so far reached Phase II proof of concept studies. In 2008 he joined the Structural Genomics Consortium at Oxford University, as PI for Chemical Biology and Project Manager for SGC's Epigenetics Chemical Probes Consortium, working on the discovery of chemical probes for bromodomains and lysine demethylases.
In January 2011 Tom joined Astex in Cambridge, UK, where he is Senior Director of Medicinal Chemistry, engaged in all aspects of drug discovery. His current interests focus on applying fragment-based lead discovery to novel and challenging targets involving protein-protein interactions, allosteric modulation and epigenetic regulation.
Tom is an FRSC and serves on the committees of the Biological and Medicinal Chemistry Sector and the Chemical Biology Interface Division of the Royal Society of Chemistry. He is a regular speaker at and organizer of medicinal chemistry and drug discovery conferences and training courses. He has authored more than 70 publications and patents.
GTC's 3rd Cancer Epigenetics Conference, one of two parallel tracks of the 2nd Cancer Summit - Novel Approaches to Drug Discovery on November 6-8 in San Francisco, CA, is the only cancer epigenetics conference that brings together leading experts from the industry and academia to collaborate on the latest cutting edge research on novel mechanisms, therapeutics, drug discovery, developments, biomarkers and diagnostics for cancer epigenetics.
Below are the sessions of the Cancer Epigenetics Conference:
I. Epigenetic Mechanisms in Cancer
II. Epigenetic Biomarkers and Diagnostics
III. Novel Epigenetic Targets in Early Development
IV. New Clinical Development of Epigenetic Drugs
V. Epigenetic Tools and Technologies
For more information, please visit http://www.gtcbio.com/cancerepigenetics.